SLGC - Earnings announcements

Revenue of $22.0 million, reflecting 14% year-over-year growth when excluding royalty revenue from NEB in the corresponding prior-year periodCash and investments of over $450 millionRaising full year 2023 revenue guidance to $82 million to $85 millionManagement to host conference call today at 4:30pm ET BOULDER, Colo., Nov. 08, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported recent business highlights and financial results for the quarter ended September 30, 2023. "We're pleased to report another quarter of solid execution, marked by commercial and operational discipline throughout the organization," said Adam Taich, Interim CEO of SomaLogi

BOULDER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the third quarter 2023 after market close on November 8, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived version of the webcast will be available at https://investors.somalogic.com/.    About SomaLogicSomaLogic is catalyzing drug research and development and biomarker identification as a global

Activates Standard BioTools' strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial cross-selling opportunities and complementary offerings Generates estimated $80 million of annual cost synergies by 2026 and enhanced combined path to profitability1 Estimated combined cash of over $500 million at close2 creates industry-leading balance sheet to fund growth initiatives Standard BioTools increases full year 2023 revenue guidance to $100 - $105 million; SomaLogic reaffirms full year 2023

Revenue of $20.5 million, an increase of 45% year-over-yearCash and investments of approximately $474 million, a strong capital position to fund current and future business initiativesReiterating full year 2023 revenue guidance and operating expense targetManagement to host conference call today at 4:30pm ET BOULDER, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter ended June 30, 2023. "Our second quarter results are in line with our expectations despite navigating operational changes and a dynamic macroeconomic backdrop. While our progress this quarter in both core assay services and distributed

BOULDER, Colo., July 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the second quarter 2023 after market close on August 14th, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived version of the webcast will be available at https://investors.somalogic.com/.    About SomaLogicSomaLogic is catalyzing drug research and development and biomarker identification as a glob

First quarter 2023 revenue of $20.4 million, representing a decrease of 11% year-over-year; excluding licensing, revenue increased 2% year-over-yearReiterating full year 2023 revenue guidance of $80-84 million Expense reduction initiatives on track and maintaining full year 2023 operating expense targetsCash and investments of $500.6 million, allowing for strategic optionality Management to host conference call today at 4:30pm ET BOULDER, Colo., May 11, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter ended March 31, 2023. "My focus at SomaLogic is fiscal discipline and commercial execution," said Adam Taich, So

BOULDER, Colo., April 20, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived version of the webcast will be available at https://investors.somalogic.com/.    About SomaLogicSomaLogic (NASDAQ:SLGC) seeks to deliver precise, meaningful, and actionable health-man

Adam Taich, EVP Life Sciences, promoted to interim CEO with a focus on operational executionBoard transition adds industry veterans: Jason Ryan as Chairman; Tycho Peterson, Kathy Hibbs, and Tom Carey as Independent DirectorsFourth quarter 2022 revenue of $18.8 million; full year 2022 revenue of $97.7 million Full year 2023 revenue guidance of $80-84 million, reflecting 12-17% growth over 2022, excluding licensing revenue from New England Biolabs Substantial balance sheet provides flexibility with cash and investments of $539.6 million at year-end 2022Working with advisors to pursue offensive strategic options including transformational opportunitiesManagement to host a conference call today

BOULDER, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, March 28, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived version of the webcast will be available at https://investors.somalogic.com/. About SomaLogicSomaLogic (NASDAQ:SLGC) seeks to deliver precise, meaningful,

Third quarter 2022 revenue of $41.7 million, bringing year to date revenue to $78.8 million.Core life science revenue of $20.5 million, representing an increase of 2.9% year-over-year and 45.4% compared to the last quarter.On track to reduce operational expenses by $75 million through 2023. Raising 2022 full year revenue guidance to a range of $93 to $98 million, taking into account the $21.2 million in licensing royalty revenue recognized in the third quarter.Cash, cash equivalents, and short-term investments of $566.3 million as of September 30, 2022. BOULDER, Colo., Nov. 14, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in AI data-driven proteomics technology, today

BOULDER, Colo. and SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in AI data-driven proteomics technology, today announced that it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022. Company management will host a corresponding audio webcast beginning at 8:30 a.m. ET. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived version of the webcast will be available at https://investors.somalogic.com/. About SomaLogicSomaLogic (NASDAQ:SLGC) seeks to deliver precise, meani

Second quarter 2022 revenue of $14.1 million, bringing year to date revenue to $37.1 million.Reducing 2022 revenue guidance to $80-90 million to account for ongoing variability in core service business, macroeconomic and commercial factors.Maintaining substantial cash, cash equivalents, and current investments of $619.1 million at quarter end; Reducing operating expenses by $75 million through 2023-end to navigate market.Ongoing strategic plans including announced acquisition of Palamedrix for next-generation SomaScan reader; Illumina protein sequencer on track for 2024 launch; accelerating broad-based initiatives to grow scale and commercial team. BOULDER, Colo., Aug. 15, 2022 (GLOBE NEW

BOULDER, Colo. , July 25, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding audio webcast beginning at 4:30 p.m. ET. Those interested in listening to the audio webcast should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at https://investors.somalogic.com/. About SomaLogicSomaLogic (NASDAQ:SLGC) seeks to deliver precise, meaningful, and actionable health-management inf

BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March 31, 2022. "Our successful first quarter has kickstarted another exciting year for SomaLogic as we continue to apply the power of the human proteome to improve health and disease management," said Roy Smythe, M.D., SomaLogic's Chief Executive Officer. "We have already reached several milestones critical to providing a variety of protein identification and measurement solutions to our customers and collaborators while expanding our database to develop impactful first-in-class diagnostic test applications. Our healthy

BOULDER, Colo., April 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 535-4027 for domestic callers or (270) 215-9487 for international callers, using conference ID: 3567018. A live audio webcast and an archive of the presentation will be available through the Investors page of SomaLogic's corporate website at https://investors.somalogic.com/. Abo

Fourth quarter 2021 revenue of $23.0 million contributed to record full year revenue of $81.6 million, 46% growth over the prior yearEstablished over 75 new customer accounts, expanding and diversifying revenue baseSubstantial cash and investments of $657.7 million at year-endMaintaining 2022 full year revenue guidance of $105-110 million Management to host conference call today at 4:30pm ET BOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter and year ended December 31, 2021. "2021 was a transformational year for SomaLogic, and we see a long runway to continue executing on o

BOULDER, Colo., March 01, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 29, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844) 535-4027 for domestic callers or (270) 215-9487 for international callers, using conference ID: 2758178. A live audio webcast and an archive of the presentation will be available through the Investors page of SomaLogic's corporate website at https://inve

Increase of 40% in third quarter revenue to $20.0 million over the corresponding period in 2020Increase of 112% in year-to-date revenue to $58.6 million over the corresponding period in 2020 Raising 2021 full year revenue guidance to $77-79 millionAddition of 61 new customer accounts expands and diversifies customer baseExpansion of leadership team with senior life science executivesSubstantial cash and investments of $676 million enabling continued growth acceleration initiatives Company to host conference call today at 8:00 a.m. ET BOULDER, Colo., Nov. 15, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the

BOULDER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the third quarter 2021 before the market opens on Monday, November 15, 2021. Company management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844) 535-4027 for domestic callers or (270) 215-9487 for international callers, using conference ID: 8689426. A live audio webcast and an archive of the presentation will be available through the Investors page of SomaLogic's corporate website at https://investors.som